Podcasts about Actavis

Speaker: Dr Stuart Baran is a barrister at specialist intellectual property chambers Three New Square IPAbstract: The UK Supreme Court has now given its long (and long-awaited) judgment in SkyKick v. Sky. It concerns the appropriate specification of goods and services as part of a trade mark application. In particular, the UKSC was asked to consider the circumstances in which a party applying for a specification broader than its intended commercial activities can be found to have applied in bad faith. The UKSC reversed the Court of Appeal on the approach in law, finding that Sky's trade mark registrations had been sought partly in bad faith, and should be partially invalidated. The Court found infringement of the remaining specification by one of SkyKick's products, but upheld the Court of Appeal's finding that there was no infringement by the other. It also found that it enjoyed a continuing jurisdiction to grant EU-wide relief given that these proceedings started before Brexit. Here I will focus on the part of the judgment about invalidity for bad faith. I will introduce what the Court has decided and its reasons, and then look at three questions: (i) to what extent does this judgment advance the law of invalidity for applying in bad faith?; (ii) is there now a difference between the extent of goods/services for which you can register your mark, and those for which you can enforce it?; and (iii) is this judgment likely to change applicants' approach to drafting their specifications?Biography: Dr Stuart Baran is a barrister at specialist intellectual property chambers Three New Square IP. After a degree in chemistry and doctorate in chemical physics, each at Oxford, he was called to the Bar in 2011 and has practised from Three New Square ever since, in all areas of IP but with particular emphases on trade marks and patents. Stuart was lucky to chair the Oxford International IP Moot for several years, starting during his DPhil. As a barrister, Stuart has appeared unled in every IP forum, from the UKIPO and European Patent Office to the EU General Court and Court of Justice as well as the UK High Court, Court of Appeal and Supreme Court. He has been involved in a number of seminal cases across the IP spectrum, including Actavis v. Lilly, Newron v. Comptroller-General, Sky v. SkyKick, and Thaler v. Comptroller-General. Alongside his private practice, Stuart is Standing Counsel to the Comptroller-General which means he represents and advises the UKIPO and government departments on intellectual property issues. He was awarded Legal 500 Junior of the Year for IP in 2018; Managing IP Junior of the Year in 2021 and 2024; and was profiled as a JUVE Patent “One to Watch” in 2023. Outside of work he is a keen orchestral violinist, cook and Italophile.For more information see: https://www.cipil.law.cam.ac.uk/seminars-and-events/cipil-seminars

Speaker: Dr Stuart Baran is a barrister at specialist intellectual property chambers Three New Square IPAbstract: The UK Supreme Court has now given its long (and long-awaited) judgment in SkyKick v. Sky. It concerns the appropriate specification of goods and services as part of a trade mark application. In particular, the UKSC was asked to consider the circumstances in which a party applying for a specification broader than its intended commercial activities can be found to have applied in bad faith. The UKSC reversed the Court of Appeal on the approach in law, finding that Sky's trade mark registrations had been sought partly in bad faith, and should be partially invalidated. The Court found infringement of the remaining specification by one of SkyKick's products, but upheld the Court of Appeal's finding that there was no infringement by the other. It also found that it enjoyed a continuing jurisdiction to grant EU-wide relief given that these proceedings started before Brexit. Here I will focus on the part of the judgment about invalidity for bad faith. I will introduce what the Court has decided and its reasons, and then look at three questions: (i) to what extent does this judgment advance the law of invalidity for applying in bad faith?; (ii) is there now a difference between the extent of goods/services for which you can register your mark, and those for which you can enforce it?; and (iii) is this judgment likely to change applicants' approach to drafting their specifications?Biography: Dr Stuart Baran is a barrister at specialist intellectual property chambers Three New Square IP. After a degree in chemistry and doctorate in chemical physics, each at Oxford, he was called to the Bar in 2011 and has practised from Three New Square ever since, in all areas of IP but with particular emphases on trade marks and patents. Stuart was lucky to chair the Oxford International IP Moot for several years, starting during his DPhil. As a barrister, Stuart has appeared unled in every IP forum, from the UKIPO and European Patent Office to the EU General Court and Court of Justice as well as the UK High Court, Court of Appeal and Supreme Court. He has been involved in a number of seminal cases across the IP spectrum, including Actavis v. Lilly, Newron v. Comptroller-General, Sky v. SkyKick, and Thaler v. Comptroller-General. Alongside his private practice, Stuart is Standing Counsel to the Comptroller-General which means he represents and advises the UKIPO and government departments on intellectual property issues. He was awarded Legal 500 Junior of the Year for IP in 2018; Managing IP Junior of the Year in 2021 and 2024; and was profiled as a JUVE Patent “One to Watch” in 2023. Outside of work he is a keen orchestral violinist, cook and Italophile.For more information see: https://www.cipil.law.cam.ac.uk/seminars-and-events/cipil-seminars

Doug Drysdale Chief Executive Officer An experienced Corporate Director and CEO: Doug has chaired the board of directors of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around three pharmaceutical companies. Doug has 30 years of experience in the healthcare sector. During this time, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents, and raised $4 billion in public and private capital. Led the turnaround of Norwich Pharmaceuticals alongside investors and became the Founding CEO of the parent company, Alvogen Group. During his 5.5-year tenure as CEO, Alvogen grew from inception to $450 million in revenues across 35 countries. In early 2014, Doug led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising $65 million. Within the first year of taking the helm as Chairman and CEO, Doug rebuilt the management team and board of directors, combined several operating locations, and grew the company's enterprise value from $80 million to around $800 million. Under Doug's leadership, Pernix raised $465 million of capital. From November 2017 to July 2020, Doug was the Director and CEO of Tedor Pharma, a family-owned contract manufacturing business. Doug's efforts to turn around the industry resulted in 60% revenue growth in 2019, leading to Tedor being recognized as one of America's fastest-growing companies and making it to the 2020 Inc 5000 list. Former Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Doug raised approximately $3 billion in capital and managed lending syndicates, including 25+ banks, to fund the company's growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion. Doug holds a bachelor's degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Ernst and Young's Entrepreneur of the Year in 2012. He is an enthusiastic traveler, having visited over 45 countries. He is also an avid reader and enjoys cooking and boating. This video was conducted on behalf of Cybin and was funded by Gold Standard Media LLC and/or affiliates. For our full disclaimer, please visit https://portal.goldstandardir.com/disclaimer/CYBN-183   https://ir.cybin.com/overview/default.aspx NYSE: CYBN I CBOE: CYBN   Addressing Mental Health Challenges Doug and Michael discussed the challenges and frustrations faced by patients and doctors in dealing with mental health issues, particularly clinical depression. With his background in building drug development companies, Doug highlighted the lack of practical tools for addressing these issues. Michael expressed his interest in innovative solutions to mental health problems, given his personal experience with clinical depression. The conversation was set to be more organic and conversational, with Doug sharing more about his company and their approach to mental health. Paradigm Shift in Drug Development Doug expressed his belief that their work has the potential to be a paradigm shift in drug development, moving from daily treatment of symptoms to more interventional therapies that can rapidly fix conditions like depression. He highlighted the promising results from their studies, with patients experiencing benefits lasting at least a year after just a couple of doses. Michael shared his personal experience with depression and burnout, emphasizing the importance of their work in addressing this widespread issue. He also asked Doug about his ability to anticipate future challenges and steps in the approval process for their work. Drug Development Challenges and Success Doug discussed the challenges and complexities of drug development, particularly in the mental health sector. He highlighted the team's experience and success in developing treatments, with 60+ INDs and 37 exits. Doug also emphasized the personal motivation of the team members, many of whom have been affected by mental health issues. He acknowledged the regulatory hurdles and administrative complexities involved in drug development but stressed the importance of these steps in creating effective treatments. Michael added that the success of the treatments could also positively impact the revenue of psychiatrists and their practices. Improving Mental Health Care Efficiency Doug discussed the potential of a new treatment to improve mental health care. He highlighted that depressed patients require a lot of attention, often visiting their physicians multiple times a year for medication adjustments and dealing with side effects. He also pointed out the shortage of psychiatrists and the long wait times for new patients. Doug suggested that their treatment, which only requires dosing once or twice, could keep patients out of the system for at least a year, freeing up resources for new patients. He also mentioned the potential for interventional psychiatry centers to see more patients if the treatment reduces the required visits. Mental Health and Metabolic Connection Michael and Doug discussed the challenges of mental health, particularly financial stress and depression. Michael shared his personal experience of overcoming depression with the help of medication and therapy and expressed his excitement about the potential of innovative work in mental health. Doug emphasized the link between metabolic health and mental health, suggesting that a poor diet can lead to reduced mental function and that mental health issues can affect an individual's metabolic health. Both agreed on the importance of addressing mental health issues to improve overall well-being and happiness. Phase 3 Program Progress and Strategy Doug discussed the progress of their phase 3 program, focusing on the challenges and complexities involved, such as drug scheduling and licensing. He expressed optimism about the potential of their treatments, citing their significant effects and the absence of dosing every day in their studies. Doug also outlined their long-term strategy, which includes leveraging their phase 3 approval in depression to treat other conditions and shift from daily chronic dosing to more interventional treatments. He emphasized the potential to break the cycle of polypharmacy and create a platform for various treatments. Michael supported their work and encouraged more people to learn about their efforts.  

Gestur Chess After Dark í dag er Róbert Wessman forstjóri og eigandi Alvotech.Umræðuefni í þættinum:- Hvaðan kemur nafnið Wessman?- Actavis tíminn- Uppbygging Alvotech- Gengi Alvotech- Lyfjageirinn almennt- Rekstur Alvotech- Er hann hræddur við vinstri stjórn?- Beefið við Bjögga Thor- Hvaðan kemur þessi áhugi á vínum?- Aðrar fjárfestingar- HjólreiðaslysiðÞetta og margt fleira.Þessi þáttur er í boði:Autocenter.Serrano.Orka Náttúrunnar.Kríta.Strúktúr.TM.Lengjan.Kontakt fyrirtækjaráðgjöf.Suit Up.Budvar.Subway.Dave&Jons.Bónus.Frumherji.Kemi.Njótið vel kæru hlustendur.

We discuss the five common reasons behind the failure of mergers, acquisitions and licensing deals  in the life sciences industry. Inadequate understanding of capability, where focusing solely on financials without comprehending the target company's regulatory and compliance processes leads to failure. The side project dilemma, illustrated by Philip Morris' venture into pharmaceuticals, emphasizing the importance of aligning with core business objectives. Clash of perspectives, exemplified by cultural and business differences between BioGene and Novartis, highlighting the necessity of alignment in strategic vision. Low margins on generic drugs, as seen in Teva's acquisition of Actavis, revealing the challenge of profitability in this sector.Overpaying, stressing the significance of thorough due diligence to avoid paying more than a company's actual value. For assistance with M&A due diligence, contact us at 302-252-6959.

This Day in Legal History: First Union FormedOn May 1, 1794, a pivotal development in labor rights history occurred in Philadelphia with the formation of the Federal Society of Journeymen Cordwainers. This organization, consisting of skilled shoemakers, marks the establishment of the first trade union in the United States. The union was created as a response to the increasingly difficult economic conditions that tradesmen faced, including low wages and long working hours.The Cordwainers, recognizing the strength in numbers, aimed to leverage their collective bargaining power to negotiate better wages and working conditions. This was a significant step forward in the labor movement, as it introduced the concept of organized labor in America. The formation of this union was not just about improving pay; it was also about dignifying the labor force and providing workers a platform to voice their concerns.Philadelphia, being a hub of commerce and trade in the late 18th century, provided the perfect setting for such an organization. The city's workshops and bustling markets meant that there was a significant demand for skilled labor, which the Cordwainers could supply. However, with industrialization beginning to take root, these skilled workers found themselves under threat from cheaper, mass-produced goods.The Federal Society of Journeymen Cordwainers set a precedent that would be followed by other trades across the country. Their actions led to the establishment of similar societies and unions, which eventually contributed to the broader national labor movement. The Cordwainers themselves faced legal challenges, particularly in 1806, when they were involved in a landmark legal case concerning the rights of workers to organize, known as Commonwealth v. Pullis. In this case, the court ruled against the union, marking one of the first legal battles over the legitimacy of trade union activities in the United States.Despite the legal setbacks, the resilience and pioneering spirit of the Federal Society of Journeymen Cordwainers inspired subsequent generations of workers to fight for their rights. Their legacy is a testament to the enduring struggle for fair labor practices and workers' rights. This day in legal history not only marks the formation of America's first trade union but also celebrates the long journey towards justice and equity in the workplace.The US Patent and Trademark Office (PTO) recently proposed a rule that would require pharmaceutical companies to submit unredacted settlement agreements involving patent challenges to a new repository. This rule is aimed to assist the Federal Trade Commission (FTC) and the Department of Justice (DOJ) in detecting antitrust violations. The proposal arose from concerns that these settlements, often reached in administrative tribunals like the Patent Trial and Appeal Board (PTAB), could be used to delay cheaper biosimilar drugs from entering the market.Evan Diamond, special counsel, noted that the PTO has not clearly defined "good cause" for accessing these agreements, which might increase third-party access and create confidentiality concerns. The fear is that the database could enable federal agencies to easily assess the frequency of potentially anticompetitive pay-for-delay settlements—a practice scrutinized under the Supreme Court's 2013 decision in FTC v. Actavis, which ruled such deals could be illegal.The proposal aligns with an executive order from President Joe Biden encouraging interagency cooperation to prevent practices that unjustifiably delay generic and biosimilar competition. This move has heightened the pharmaceutical industry's fears of increased antitrust enforcement, particularly as the FTC has been actively challenging questionable patent listings that could hinder the approval of generic drugs.Agencies like the FTC and DOJ already have certain reporting requirements under the Medicare Modernization Act for pharmaceutical companies, but the PTO's rule could capture additional agreements that do not meet existing criteria. This has sparked debate over the necessity and potential overlap of the new rule.The pharmaceutical industry, represented by major lobbyist groups like Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization, has expressed strong opposition, citing concerns over the scope of PTO's authority and the ambiguity around the "good cause" criterion.This development highlights a broader regulatory push against anti-competitive practices not only in pharmaceuticals but also in other sectors like technology, where companies like Apple and Google are frequently involved in patent litigation.In summary, the PTO's proposed rule could significantly impact how pharmaceutical settlements are handled, potentially exposing companies to greater antitrust scrutiny. This measure reflects a governmental shift towards stricter oversight of patent practices to foster competition and reduce drug prices.Drug Makers Exposed to Antitrust Probes if Patent Cache AdoptedThis term, Jones Day had the highest number of attorneys—five in total—arguing cases at the U.S. Supreme Court, more than any other firm. Among them, John Gore and C. Kevin Marshall presented for the first time at the high court. Other experienced attorneys like former U.S. Solicitor General Noel Francisco, and partners Hashim Mooppan and Traci Lovitt also argued cases, contributing to the firm's visibility.In comparison, other leading law firms such as Gibson Dunn, Hogan Lovells, and Williams & Connolly had slightly fewer representatives. Gibson Dunn introduced three new attorneys to the Supreme Court lectern, including Theane Evangelis, D. Nick Harper, and Eugene Scalia, who is a son of the late Justice Antonin Scalia. Hogan Lovells' Jessica Ellsworth argued for the first time, including in a significant case regarding the abortion drug mifepristone. Williams & Connolly had Lisa Blatt argue all four of their cases, marking her 50th Supreme Court appearance.Overall, the season saw a mix of seasoned veterans and newcomers. Of the total 152 arguments made, over half were by attorneys who had appeared at least five times before, while a quarter were by first-time arguers. This highlights both the depth of experience and the ongoing introduction of new talent in the legal field's highest echelons.Jones Day Leads in Supreme Court Arguments With New FacesJohnson & Johnson (J&J) is currently seeking approval for an $11 billion settlement to resolve ongoing litigation concerning its talc-based baby powder, which has been alleged to cause ovarian cancer. This amount is a significant increase from a previous offer of $8.9 billion. J&J's strategy involves a third attempt at a bankruptcy filing, specifically a pre-packaged bankruptcy, which allows for faster processing if they secure enough creditor support—in this case, needing the approval of 75% of the talc plaintiffs.The company proposes to pay $6.48 billion over 25 years to settle ovarian cancer claims, but it has not specified how funds will be divided between existing and future claims. Additionally, J&J has nearly settled all claims regarding mesothelioma believed to be caused by asbestos in the powder. This settlement approach follows multiple failed attempts to use Chapter 11 to manage these lawsuits, which now number almost 60,000.These lawsuits have been a significant factor depressing J&J's stock price, according to analysts. Despite the legal challenges, J&J maintains that its talc products do not cause cancer and asserts that it has marketed its baby powder responsibly for over a century. A recent verdict, however, led to a $45 million payout to a family, implicating J&J and its spinoff Kenvue in the ongoing litigation.The company's persistence in seeking a bankruptcy-based settlement reflects its strategic approach to managing a complex legal challenge that impacts thousands of plaintiffs and could potentially set a precedent in how large corporations handle mass tort liabilities through bankruptcy court.J&J Seeks Backing for $11 Billion Baby Powder Cancer SettlementIn President Joe Biden's Fiscal Year 2025 Budget Proposal, a notable change is the suggestion to tax unrealized gains—value increases in assets not yet converted into cash through a sale. This marks a significant shift from traditional tax frameworks, which typically avoid taxing unrealized gains due to their complexity, potential liquidity issues, and difficulties in implementation.The rationale behind this proposal is to ensure tax fairness by capturing increases in wealth that currently escape taxation. For example, if a billionaire's stock appreciates significantly without being sold, they realize no taxable gain. However, if they borrow against these increased values, they effectively use this appreciation as a means to generate wealth without incurring tax liabilities. This situation presents a loophole where wealth can grow and be leveraged without contributing to the tax base.The FY2025 budget aims to address these disparities by proposing a tax on unrealized gains for very high-net-worth individuals and entities that have not been subject to a tax event in the last 90 years. This approach seeks to broaden the tax base without raising rates, aiming to increase tax revenue from the wealthy without additional burdens on middle and lower-income individuals.This policy shift acknowledges the need to adapt tax strategies to a changing economic environment where traditional taxation methods no longer capture all forms of wealth accumulation. The proposal suggests that a more equitable tax system requires taxing wealth as it grows, even if it is not realized through a sale. By proposing to tax unrealized gains, the administration intends to correct imbalances allowing substantial wealth to accumulate tax-free, signaling a significant potential change in how wealth is taxed in the U.S.Unrealized Gain Tax—A Coming Sea Change in FY2025 Budget Proposal? Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

Ten years ago, the U.S. Supreme Court issued its 5-3 decision in FTC v. Actavis, which held that the rule of reason should govern so-called "pay-for-delay" patent litigation settlement agreements between brand name and generic pharmaceutical manufacturers. In this episode, hosts Aaron Yeater and Alicia Downey talk to Kristen O'Shaughnessy and Dan Grossbaum about how the decision has shaped litigation in the years since and its implications for antitrust challenges in other industries. Listen to this episode to learn about the impact of the Actavis decision in the past ten years and in the future. With special guests: Kristen O'Shaughnessy, Partner, White & Case and Daniel Grossbaum, Associate, White & Case Related Links: FTC v. Actavis: Opinions and Oral Arguments Hosted by: Alicia Downey, Principal, Downey Law LLC and Aaron Yeater, Managing Principal, Analysis Group

In this exclusive interview with Dr. Grant Stevens, we are honored to present an intimate conversation with the Father of Medical Aesthetics, Dr. David Pyott.Acknowledged as one of the top 100 performing CEO's in the world, Dr. Pyott was the Chief Executive Officer of Allergan from 1998 until the sale of the company to Actavis in 2015. By driving innovation through investments in R&D and impeccable performance, Dr. Pyott transformed Allergan from a small eye care company into a multi-billion dollar global specialty pharmaceutical and medical device company, overseeing $68 billion in market value growth. During his tenure Allergan launched blockbuster treatments that transformed medicine and skincare including expanding the approved uses of Botox to include treatment of migraine headaches, chronic tension headaches, cerebral palsy, severe over-active bladder and such cosmetic uses as brow furrows and crow's feet.Throughout his career, Dr. Pyott has earned a number of honors and awards for his contributions to business, including the 2006 honor of Commander of the Most Excellent Order of the British Empire (CBE) awarded by Her Majesty the Queen for his contribution to British business excellence and management skills in the United States; the 2013 Orange County Council Semper Fidelis award for his outstanding service to the community; The Medal - University of California, Irvine's most prestigious honor in 2010; Executive Leader of the Year, UCLA Anderson School of Management 2012 and Harvard Business Review's 4th best-performing CEO in the World – 2014.Show Notes:0:00 Intro1:04 Background10:25 This little company called Allergan popped up12:53 The very beginning of Botox16:52 April 15, 2001: The best tax day ever20:00 Juvéderm acquisition24:24 The birth of medical aesthetics26:00 Marketing mechanics: seizing opportunities, world markets33:18 We have an absolute jewel hiding in our own safe35:38 Market creation as a series of concentric rings38:53 Looking better, feeling better46:04 What David is doing now51:47 On transcutaneous delivery53:47 Duration of toxins1:01:28 Natural combination of toxin and fillers1:02:56 Plug-in devices1:07:04 David's crystal ball» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/

Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm, Sweden in the late 1960's where he spent over a decade as an immigrant worker and entrepreneur. As a nurse assistant, operation room tech and critical care tech at the Royal Medical College Infirmary in Stockholm, he experienced first hand the failures of allopathic medicine in the treatment and prevention of disease. Dissatisfied with so all modern medicine Tarik decided to leave the medical field and made a niche for himself in the publishing business gaining a strong background as a researcher and linguist Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity

  ELDER RAY FAUNTROY: FOUNDER THE GRASSROOTS ASSEMBLY (TPGA) A NEW DAY-A NEW WAY Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm, Sweden in the late 1960's where he spent over a decade as an immigrant worker and entrepreneur. As a nurse assistant, operation room tech and critical care tech at the Royal Medical College Infirmary in Stockholm, he experienced first hand the failures of allopathic medicine in the treatment and prevention of disease. Dissatisfied with so all modern medicine Tarik decided to leave the medical field and made a niche for himself in the publishing business gaining a strong background as a researcher and linguist

2/3/23 Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm, Sweden in the late 1960's where he spent over a decade as an immigrant worker and entrepreneur. As a nurse assistant, operation room tech and critical care tech at the Royal Medical College Infirmary in Stockholm, he experienced first hand the failures of allopathic medicine in the treatment and prevention of disease. Dissatisfied with so all modern medicine Tarik decided to leave the medical field and made a niche for himself in the publishing business gaining a strong background as a researcher and linguist ELDER RAY FAUNTROY: FOUNDER THE GRASSROOTS ASSEMBLY (TPGA) A NEW DAY-A NEW WAY Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity  

ELDER RAY FAUNTROY: FOUNDER THE GRASSROOTS ASSEMBLY (TPGA) A NEW DAY-A NEW WAY Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm, Sweden in the late 1960's where he spent over a decade as an immigrant worker and entrepreneur. As a nurse assistant, operation room tech and critical care tech at the Royal Medical College Infirmary in Stockholm, he experienced first hand the failures of allopathic medicine in the treatment and prevention of disease. Dissatisfied with so all modern medicine Tarik decided to leave the medical field and made a niche for himself in the publishing business gaining a strong background as a researcher and linguist

Molly Burch, Suede Island, Cigarettes' After Sex & Le Cassette Chopped & Screwed By Schizophrenic God AKA SKAeM FKA SKAM.. released November 17, 2020

#CHOPPEDANDSCREWED #MSKOD #SKAeMDEMO Preview. Version 1 dMC. / RARE CHOPPED & SCREWED Including HOLLYWOODGBABY, SCHIZOPHRENIC GOD & CRIS TRIALZ [Tracks] Cris Trialz - Soul Service (Prod. By Swirl) Schizophrenic God - Snippet (Unreleased Dose) Hollywood G Baby - What You Want (Prod. By Dee B) Hollywood G Baby - Let It Drip Feat. Cris Trialz (Prod. By Beat Klique) Schizophrenic God - Interlude Hollywood G Baby - Baphomet Feat. Cris Trialz(Prod. By Heavy Keyzz) Hollywood G Baby - Back Around (Prod. By MB13Beatz)

RARE TAPE By Schizophrenic God AKA SKAeM

WEATHER WARFARE AGAINST THE WORLDS PEOPLE!!  MILITARY INDUSTRIAL CON PLEX, $30 trillion in the RED!  UNACCOUNTED FOR BY THE VERY HIERARCHY BROUGHTHERE1944, OPERATION PAPER CLIP! Come together, or Perish in the Coming  HARD Rain , falling and being MADE BY H.A.A.R.P ELDER RAY FAUNTROY: FOUNDER THE GRASSROOTS ASSEMBLY (TPGA) A NEW DAY-A NEW WAY Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm, Sweden in the late 1960's where he spent over a decade as an immigrant worker and entrepreneur. As a nurse assistant, operation room tech and critical care tech at the Royal Medical College Infirmary in Stockholm, he experienced first hand the failures of allopathic medicine in the treatment and prevention of disease. Dissatisfied with so all modern medicine Tarik decided to leave the medical field and made a niche for himself in the publishing business gaining a strong background as a researcher and linguist.

ELDER RAY FAUNTROY: FOUNDER THE GRASSROOTS ASSEMBLY (TPGA) A NEW DAY-A NEW WAY Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm, Sweden in the late 1960's where he spent over a decade as an immigrant worker and entrepreneur. As a nurse assistant, operation room tech and critical care tech at the Royal Medical College Infirmary in Stockholm, he experienced first hand the failures of allopathic medicine in the treatment and prevention of disease. Dissatisfied with so all modern medicine Tarik decided to leave the medical field and made a niche for himself in the publishing business gaining a strong background as a researcher and linguist.

12/23/2022 WHAT DO YOU THINK, TELL US YOUR OPINION ELDER RAY FAUNTROY: FOUNDER "THE GRASSROOTS ASSEMBLY (TPGA) A NEW DAY-A NEW WAY" Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity  

ELDER RAY FAUNTROY: FOUNDER THE GRASSROOTS ASSEMBLY (TPGA) A NEW DAY-A NEW WAY Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity Tarik El is a lay researcher and information archivist. He received his training in anatomy, physiology and allopathic medical nursing in Stockholm, Sweden in the late 1960's where he spent over a decade as an immigrant worker and entrepreneur. As a nurse assistant, operation room tech and critical care tech at the Royal Medical College Infirmary in Stockholm, he experienced first hand the failures of allopathic medicine in the treatment and prevention of disease. Dissatisfied with so all modern medicine Tarik decided to leave the medical field and made a niche for himself in the publishing business gaining a strong background as a researcher and linguist.

Viðmælandi þáttarins er Jónína Guðmundsdóttir, forstjóri Coripharma. Coripharma er íslenskt nýsköpunarfyrirtæki í Hafnarfirði sem sérhæfir sig í þróun og framleiðslu samheitalyfja fyrir önnur lyfjafyrirtæki. Félagið var stofnað árið 2018 en nú starfa þar um 160 manns. Jónína er fædd árið 1972 og er alin upp í Kópavoginum þar sem hún gekk í grunnskóla. Hún fór í Menntaskólann í Hamrahlíð og kláraði Masterspróf í lyfjafræði frá Háskóla Íslands. Jónína starfaði í um sextán ár hjá Medis, dótturfélagi Actavis, sem síðar var selt til Teva árið 2016. Medis sérhæfir sig í sölu á lyfjahugviti og samheitalyfjum til annarra lyfjafyritækja um allan heim. Hjá Medis gengdi Jónína ýmsum stjórnendastöðum, leiddi m.a. viðskiptaþróun félagsins auk þess að vera staðgengill forstjóra. Þegar Jónína hætti hjá Medis var félagið með um 110 starfsmenn í 10 löndum, með sölu á 250 lyfjum og veltu um 500 milljóna evra. Jónína hefur einnig setið í ýmsum stjórnum eins og í stjórn Samtaka Iðnaðarins, Samtaka Atvinnulífins, Medis Pharma á Íslandi sem og í Hollandi. Þátturinn er kostaður af Icelandair.

An experienced Corporate Director and CEO, Doug Drysdale has chaired the Board of a NASDAQ-listed company and, as CEO for the past 14 years, has built and turned around 4 pharmaceutical companies. During Doug's 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised around $4 billion of both public and private capital. Find out more about Cybin here and follow Doug on LinkedIn.Previously, Doug was Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including over 25 banks, to fund the company's growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.Discover more:Interested in coaching services, check out Live for Yourself Consulting and Dr. Benjamin Ritter

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” of IP litigations between makers of branded small molecule drugs and generics requires an analysis under the rule of reason. Are there distinct challenges presented by settlements between branded biologics and biosimilars? Sean Sheridan and Archan Ruparel, principals at Charles River Associates, speak with Anora Wang and Christina Ma on the complexities of negotiating patent settlements involving biosimilars. Listen to this episode to learn about pharmaceutical entry, price erosion, and more. With special guests: Sean Sheridan, Principal, Charles River Associates and Archan Ruparel, Principal, Charles River Associates Related Link: Sean Sheridan and Archan Ruparel, FDA Biosimilar Approval Foreshadows IP Litigation Issues (September 15, 2021) Hosted by: Anora Wang, Arnold & Porter and Christina Ma, Wachtell, Lipton, Rosen & Katz

Hildur Elín Vignir og Adriana Karólína Pétursdóttir stjórnarkonur í Mannauði, félagi mannauðsfóks á Íslandi mættu til okkar í byrjun þáttar í tilefni Alþjóðlega mannauðsdagsins sem er í dag. Á dögunum var tilkynnt að Davíð Helgason fjárfestir og Kjartan Örn Ólafsson frumkvöðull og tæknifjárfestir stæðu nú að stofnun fyrirtækisins Transition Labs sem ætlað er að laða erlend loftslagsfyrirtæki hingað til lands. Kjartan Örn var gestur okkar í dag. Greint hefur verið frá því að ennþá vanti starfsfólk í ferðaþjónustu sem er að einhverju leyti farin að taka við sér eftir faraldurinn - og framkvæmdastjóri Samtaka ferðaþjónustunna hefur sagt að það gæti komið t il þess að flytja þurfi inn fólk til að manna störf í atvinnugreininni. Þá kallar fjölgun nýbygginga sömuleiðis á erlent vinnuafl. Við ræddum við Hannes G. Sigurðsson, hagfræðing hjá Samtökum atvinnulífsins, um vinnuafl og mannfjölda - og nauðsynlega innviðauppbyggingu. Venju samkvæmt förum við yfir fréttir vikunnar á föstudögum. Í þetta skiptið komu til okkar Valur Grettisson, ritstjóri Reykjavík Grapevine, og Heiða Kristín Helgadóttir, framkvæmdastjóri. Í nýlegri alþjóðlegri rannsókn komust vísindamenn að því að þeir sem voru að fá minna en 40% orku sinnar frá kolvetnum voru með 20% hærri dánartíðni en þeir sem fengu á bilinu 50-55% orkunnar frá kolvetnum. Nýleg rannsókn Landlæknisembættisins komst svo að því að samkvæmt þessu eru Íslendingar einfaldlega að borða allt of lítið af kolvetnum, þ.e. alla jafna fáum við um 37% af orku okkar úr kolvetnum. Við ræddum þessa heitu kartöflu, þ.e. kolvetnin, við Jóhönnu Eyrúnu Torfadóttur verkefnastjóra næringar hjá Landlæknisembættinu. Í ítarlegri úttekt Stundarinnar má finna upplýsingar þess efnis að íslenskir lífeyrissjóðir hafi hagnast um tugi milljarða á viðskiptum sínum við íslenska fyrirtækið Actavis sem, samkvæmt fréttum fjölmiðilsins, ber að hluta ábyrgð í miklum ópíóðafaraldri í Bandaríkjunum sem kostað hefur um hálfa milljón manns lífið. Þetta vekur upp spurningar um samfélagslega ábyrgð lífeyrissjóðanna sem vinna eftir ríkri kröfu um ávöxtun lífeyris alls launafólks - en hvað má sú ávöxtun kosta og hvaða skyldur ríkja á lífeyrissjóðunum að taka upplýstar ákvarðanir um fjárfestingar sínar? Við ræddum þessi mál við Ólaf Sigurðsson framkvæmdastjóra lífeyrissjóðsins Birtu. Tónlist: Little By Little - Lay Low As it Was - Harry Styles Wonderful Life - Hurts Running Into a Wall - Seabear La Flamme - Sycamore Tree Video Games - Lana Del Rey Landsímalína - Spilverk Þjóðanna Vesturbæjar Beach - BSÍ

Hildur Elín Vignir og Adriana Karólína Pétursdóttir stjórnarkonur í Mannauði, félagi mannauðsfóks á Íslandi mættu til okkar í byrjun þáttar í tilefni Alþjóðlega mannauðsdagsins sem er í dag. Á dögunum var tilkynnt að Davíð Helgason fjárfestir og Kjartan Örn Ólafsson frumkvöðull og tæknifjárfestir stæðu nú að stofnun fyrirtækisins Transition Labs sem ætlað er að laða erlend loftslagsfyrirtæki hingað til lands. Kjartan Örn var gestur okkar í dag. Greint hefur verið frá því að ennþá vanti starfsfólk í ferðaþjónustu sem er að einhverju leyti farin að taka við sér eftir faraldurinn - og framkvæmdastjóri Samtaka ferðaþjónustunna hefur sagt að það gæti komið t il þess að flytja þurfi inn fólk til að manna störf í atvinnugreininni. Þá kallar fjölgun nýbygginga sömuleiðis á erlent vinnuafl. Við ræddum við Hannes G. Sigurðsson, hagfræðing hjá Samtökum atvinnulífsins, um vinnuafl og mannfjölda - og nauðsynlega innviðauppbyggingu. Venju samkvæmt förum við yfir fréttir vikunnar á föstudögum. Í þetta skiptið komu til okkar Valur Grettisson, ritstjóri Reykjavík Grapevine, og Heiða Kristín Helgadóttir, framkvæmdastjóri. Í nýlegri alþjóðlegri rannsókn komust vísindamenn að því að þeir sem voru að fá minna en 40% orku sinnar frá kolvetnum voru með 20% hærri dánartíðni en þeir sem fengu á bilinu 50-55% orkunnar frá kolvetnum. Nýleg rannsókn Landlæknisembættisins komst svo að því að samkvæmt þessu eru Íslendingar einfaldlega að borða allt of lítið af kolvetnum, þ.e. alla jafna fáum við um 37% af orku okkar úr kolvetnum. Við ræddum þessa heitu kartöflu, þ.e. kolvetnin, við Jóhönnu Eyrúnu Torfadóttur verkefnastjóra næringar hjá Landlæknisembættinu. Í ítarlegri úttekt Stundarinnar má finna upplýsingar þess efnis að íslenskir lífeyrissjóðir hafi hagnast um tugi milljarða á viðskiptum sínum við íslenska fyrirtækið Actavis sem, samkvæmt fréttum fjölmiðilsins, ber að hluta ábyrgð í miklum ópíóðafaraldri í Bandaríkjunum sem kostað hefur um hálfa milljón manns lífið. Þetta vekur upp spurningar um samfélagslega ábyrgð lífeyrissjóðanna sem vinna eftir ríkri kröfu um ávöxtun lífeyris alls launafólks - en hvað má sú ávöxtun kosta og hvaða skyldur ríkja á lífeyrissjóðunum að taka upplýstar ákvarðanir um fjárfestingar sínar? Við ræddum þessi mál við Ólaf Sigurðsson framkvæmdastjóra lífeyrissjóðsins Birtu. Tónlist: Little By Little - Lay Low As it Was - Harry Styles Wonderful Life - Hurts Running Into a Wall - Seabear La Flamme - Sycamore Tree Video Games - Lana Del Rey Landsímalína - Spilverk Þjóðanna Vesturbæjar Beach - BSÍ

Hildur Elín Vignir og Adriana Karólína Pétursdóttir stjórnarkonur í Mannauði, félagi mannauðsfóks á Íslandi mættu til okkar í byrjun þáttar í tilefni Alþjóðlega mannauðsdagsins sem er í dag. Á dögunum var tilkynnt að Davíð Helgason fjárfestir og Kjartan Örn Ólafsson frumkvöðull og tæknifjárfestir stæðu nú að stofnun fyrirtækisins Transition Labs sem ætlað er að laða erlend loftslagsfyrirtæki hingað til lands. Kjartan Örn var gestur okkar í dag. Greint hefur verið frá því að ennþá vanti starfsfólk í ferðaþjónustu sem er að einhverju leyti farin að taka við sér eftir faraldurinn - og framkvæmdastjóri Samtaka ferðaþjónustunna hefur sagt að það gæti komið t il þess að flytja þurfi inn fólk til að manna störf í atvinnugreininni. Þá kallar fjölgun nýbygginga sömuleiðis á erlent vinnuafl. Við ræddum við Hannes G. Sigurðsson, hagfræðing hjá Samtökum atvinnulífsins, um vinnuafl og mannfjölda - og nauðsynlega innviðauppbyggingu. Venju samkvæmt förum við yfir fréttir vikunnar á föstudögum. Í þetta skiptið komu til okkar Valur Grettisson, ritstjóri Reykjavík Grapevine, og Heiða Kristín Helgadóttir, framkvæmdastjóri. Í nýlegri alþjóðlegri rannsókn komust vísindamenn að því að þeir sem voru að fá minna en 40% orku sinnar frá kolvetnum voru með 20% hærri dánartíðni en þeir sem fengu á bilinu 50-55% orkunnar frá kolvetnum. Nýleg rannsókn Landlæknisembættisins komst svo að því að samkvæmt þessu eru Íslendingar einfaldlega að borða allt of lítið af kolvetnum, þ.e. alla jafna fáum við um 37% af orku okkar úr kolvetnum. Við ræddum þessa heitu kartöflu, þ.e. kolvetnin, við Jóhönnu Eyrúnu Torfadóttur verkefnastjóra næringar hjá Landlæknisembættinu. Í ítarlegri úttekt Stundarinnar má finna upplýsingar þess efnis að íslenskir lífeyrissjóðir hafi hagnast um tugi milljarða á viðskiptum sínum við íslenska fyrirtækið Actavis sem, samkvæmt fréttum fjölmiðilsins, ber að hluta ábyrgð í miklum ópíóðafaraldri í Bandaríkjunum sem kostað hefur um hálfa milljón manns lífið. Þetta vekur upp spurningar um samfélagslega ábyrgð lífeyrissjóðanna sem vinna eftir ríkri kröfu um ávöxtun lífeyris alls launafólks - en hvað má sú ávöxtun kosta og hvaða skyldur ríkja á lífeyrissjóðunum að taka upplýstar ákvarðanir um fjárfestingar sínar? Við ræddum þessi mál við Ólaf Sigurðsson framkvæmdastjóra lífeyrissjóðsins Birtu. Tónlist: Little By Little - Lay Low As it Was - Harry Styles Wonderful Life - Hurts Running Into a Wall - Seabear La Flamme - Sycamore Tree Video Games - Lana Del Rey Landsímalína - Spilverk Þjóðanna Vesturbæjar Beach - BSÍ

Helgi Seljan ræðir við blaðamenn Stundarinnar um efni nýjasta tölublaðsins. Í forsíðuumfjölluninni er meðal annars sagt frá því að íslenska lyfjafyrirtækið Actavis seldi 32 milljarða taflna, eða þriðjung allra morfínlyfja í Banda­ríkjunum 2006 til 2012, á meðan notkun slíkra lyfja varð að faraldri í landinu. Fyrirtækinu var stýrt af Róberti Wessman hluta tímans og var í eigu Björgólfs Thors Björgólfssonar allan tímann.

Helgi Seljan ræðir við blaðamenn Stundarinnar um efni nýjasta tölublaðsins. Í forsíðuumfjölluninni er meðal annars sagt frá því að íslenska lyfjafyrirtækið Actavis seldi 32 milljarða taflna, eða þriðjung allra morfínlyfja í Banda­ríkjunum 2006 til 2012, á meðan notkun slíkra lyfja varð að faraldri í landinu. Fyrirtækinu var stýrt af Róberti Wessman hluta tímans og var í eigu Björgólfs Thors Björgólfssonar allan tímann.

On this episode Leo interviews Patrick Daly. He is the Managing Director of Alba Consulting since 2005 and works with many of the top Fortune 500 companies in manufacturing, distribution and logistics services in Europe, Asia and the Americas helping them to achieve dramatic improvements in their supply chain capabilities and performance through supply chain excellence. In his consultancy assignments, Patrick has worked with clients all over the world in countries such as China, India, Uruguay, Puerto Rico, Egypt, UAE, US, UK, Spain, Croatia and others, clients include Pfizer, Abbott Vascular, Stryker, Braun, GSK, Merck Millipore, Actavis, Astellas, Pepsi Worldwide Flavours, Glanbia and Ornua among others. Patricks hosts Interlinks, a weekly radio programme broadcast on Dublin South FM that explores relayed to international business, supply chain and logistics around the world through the medium of interviews with business people from around the world and he is the author of the book International Supply Chain Relationships: Creating Competitive Advantage in a Globalized Economy published by Kogan Page in London and New York in 2019. He has also the author of the booklet Warehouse Strategy, Design, and Operation in 2017 and co-author of the recently published e-book Thriving in the New Business Environment: Why the Strategic Supply Chain Matters.Patrick in an active member of the National Logistics Forum in Ireland set up by the Department of Transport, Trade and Tourism in April 2020 to advise the Irish government on keeping supply lines open during and after the COVID19 pandemic.Patrick holds a BSc Hons degree in Technology and worked in manufacturing industry in engineering design, R&D, product development and international commercial technical roles in the storage equipment industry in both Spain and Ireland prior to establishing his consultancy business. Connect with Patrick on LinkedIn Alba Consulting websiteInterlinks podcast Self-learning is of paramount importance in the business world, listen to your international peers and step up your game.Connect with the host Leonardo Marra on LinkedIn Follow the page on LinkedIn **This episode is sponsored by International Expansion Explained. Are you looking to expand internationally, but you're not sure where to start? Or you export already but would like to venture further overseas? Reach out to arrange an international clarity session and learn more about growth plans here International Expansion StrategyPartners SearchOngoing sales and branding supportIndividual one on one support

Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity 

Elder Raymond Fauntroy former SCLC president, Civic right Actavis, singer & Dr Martin Luther King driver.We're looking at the pass to build for now and the future, Elder Raymond Fauntroy brother of Walter Raymond. Also,we're looking at The African American National United...William T. Fauntroy One of the original Tuskegee Airman had his 95th birthday celebrated Sunday with a motor parade in front of his home Sunday in Northeast Washington, At 3:00 every Sunday beat your drums for power of unity https://www.gofundme.com/f/kim-weston

In this week's Dealmaker Show Interview, Oren will talk to Doug Drysdale on Biohacking and Psychedelics. Doug Drysdale has chaired the board of directors of a NASDAQ-listed company and as a CEO for the past 13 years has built and turned around four pharmaceutical companies. During Doug's 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, and has raised $4 billion of both public and private capital. Previously, Doug served as Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including over 25 banks, to fund the company's growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion. Doug holds a bachelor's degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 6 Dr. Packer reflects on a conversation he had with Dr. Eugene Braunwald about mentorship and its role in immortality. This episode is particularly meaningful to the CardioNerds team as mentorship and sponsorship is such an important part of the CardioNerds mission. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 4, Dr. Packer shares his perspective on the revolutionary SGLT2 inhibors. We discuss the mechanisms of action and the data regarding their role in the care of heart failure patients. This episode is particularly historic in that Dr. Packer shares his thoughts about the EMPEROR-PRESERVED trial well before the data was available. Also see Dr. Mark Belkin's DocWire News article EMPEROR's New Groove? Empagliflozin Provides Long-Awaited Treatment for HFpEF where Dr. Packer is quoted as saying “we are pleased to have the first trial in patients with HFpEF that shows an unequivocally positive and clinically important result. We are looking forward to many secondary papers that will provide detailed information about what we have found, and what it means for patients.” Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 5, Dr. Packer shares his thoughts on the term “guideline directed medical therapy,” guidelines in general, and the challenges of using the ejection fraction to measure systolic function. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 3 Dr. Packer reflects on the value of neutral trials and recounts the journey that led to the PARADIGM Trial Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 2 Dr. Packer shares his journey as the trailing spouse and tells the story of how the neurohormonal hypothesis was developed. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 1 Dr. Packer discusses taking risks, upsetting people and the ridiculousness of humanity and how stand-up comedy helped contribute and shape his career in cardiovascular medicine. Dr. Packer also discusses how the study of afterload agents in heart failure and the discovery of tachyphylaxis with prazosin helped inspire a long and prosperous career in academic cardiology by changing the status quo. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.

The Knicks were sleepwalking in Atlanta, what a trip

Christine Ann Miller has served as President and Chief Executive Officer and as a member of the board of Melinta Therapeutics since August 2020. Ms. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences. She directed more than 50 product launches that generated over $300 million of new annual revenue, closed numerous business development acquisitions, and built a robust five-year development and acquisition product pipeline. Before Sandoz, Ms. Miller spent over a decade at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals where she led the preparation of numerous product launches and held leadership roles in both R&D operations and supply chain management. Christine started her career at Merck as a chemical engineer and procurement analyst and earned an MBA and a Master's in Technology Management at Stevens Institute of Technology and a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute. In this episode, we discuss: ·     The root of Christine's purpose and how where she came from inspired her journey. ·     How knowing her purpose helped achieve goals and climb the ladder throughout her career. ·     The redefinition of power through knowing it actually sits within you– you don't have to chase it, or take it from someone else to be powerful. ·     How, as a CEO, Christine has faced both political challenges and professional challenges to her power and has used her strength of purpose to intentionally stay in her power. I hope you will find this episode as exciting and informative as I have.  Please let me know your thoughts!   Connect with Christine Miller Website: https://melinta.com/ LinkedIn: https://www.linkedin.com/in/christinemiller95/  Connect with Dr. Sharon Melnick Website: https://www.sharonmelnick.com/ LinkedIn: https://www.linkedin.com/in/sharonmelnick/ Learn more about your ad choices. Visit megaphone.fm/adchoices

What is it really like to be the UK Supreme Court's leading decision maker, interpreting some of the most important intellectual property decisions of recent times? In the latest podcast in our 'In Conversation with Gowling WLG' series, global IP partner Ron Dimock speaks to the Right Honourable Lord Neuberger of Abbotsbury, former President of the United Kingdom Supreme Court. In this episode, we delve deep into the world of patent law, exploring some of the most important decisions in international IP, and the difficulties and privileges of interpreting some of the sectors most important cases We explore: Lord Neuberger's career from Oxford University science grad to private practice lawyer, admittance to the Bar, and his surge up the judicial ranks to President of the UK Supreme Court; Patents judgement, hearing IP and patent cases, and the unique challenges of trying intellectual property claims; Complex, precedent setting cases from Lord Neuberger's career, including Catnic Components Ltd. v. Hill & Smith Ltd., Kirin-Amgen Inc. v Hoechst Marion Roussel Ltd, and Actavis v Eli Lilly, and their impact on the approach to infringement. The interpretation of patents, the European Patent convention and the introduction of the doctrine of equivalents; The key developing patent issues to be litigated in the foreseeable future, the impact of COVID-19 on future IP cases, and the demanding nature of internationalising consistent laws across countries; and Much more.

Brent Saunders has over 25 years of experience in various aspects of healthcare and has been in leadership roles at several prominent global pharmaceutical and healthcare companies. Until May 2020, when it was acquired by AbbVie Inc. in a transaction valued at approximately $63 billion, Mr. Saunders served as Chairman, President and Chief Executive Officer of Allergan plc. His role as President and Chief Executive Officer of Allergan began in July 2014 and his added role of Chairman began in October 2016. Mr. Saunders first role as an executive officer in the pharmaceuticals and healthcare sectors began in 2003, as a member of the executive management team at Schering-Plough Corporation, where he held several key roles, including President of the company’s Global Consumer Health Care division. While at Schering-Plough, Mr. Saunders led the integrations of the company’s $14 billion acquisition of Organon Biosciences N.V in 2007 as well as the merger between Schering-Plough and Merck & Co., Inc. in 2009. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, a leading global eye health company, until its acquisition by Valeant Pharmaceuticals, Inc. in 2013. He then became the Chief Executive Officer of Forest Laboratories Inc., a role he held until the company’s merger with Actavis plc in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business. In 2015, he led Actavis’ acquisition of Allergan, renaming the combined company Allergan Plc. Learn more about Vesper Health: https://www.vesperhealth.com/ Follow Brent Saunders on Instagram: https://www.instagram.com/brentlsaunders/?hl=en Follow Brent Saunders on Twitter: https://twitter.com/brentlsaunders - Follow me on Instagram: https://instagram.com/casey

In this episode, we interview Matthew Maletta, executive vice president and chief legal officer of Endo Pharmaceuticals. Matthew was appointed in May 2015 to these roles at Endo Pharmaceuticals, where he has global responsibility for all legal matters affecting the company.  Prior to joining Endo in 2015, he served as vice president, associate general counsel, and corporate secretary of Allergan. In this position, he served as an advisor to the chief executive officer and board of directors and supervised several large transactions, including the $70 billion acquisition of Allergan by Actavis in 2015.

Teej & Nick discuss the top southern rappers ever, the evolution of Hot Girl Summer, and why you need to keep the strap on you!

Shyam Mohan is a passionate Total Rewards leader with a wide array of experience building and implementing global compensation and benefit programs and solutions. He brings a strategic focus prioritizing the employee experience while balancing costs and business needs.He has two Master’s degrees from Rutgers University in Human Resource Management and Employee & Labor Relations. Shyam started his career at Johnson & Johnson in recruiting, but quickly moved into compensation & HRIS. He then joined Watson Labs, a generics company that was on the cusp of transformative M&A activity. Here he got extensive experience with M&A’s as Watson acquired many companies growing into the multinational generics company, Actavis, and finally acquiring Allergan creating a global brands and generics leader. As the company grew, Shyam’s roles within the company continued to grow and he became a trusted compensation advisor to HR and business leaders.His time with Allergan culminated with him leading all compensation & benefits activity for the divestiture of the Actavis generics business to Teva. Shyam’s next role was with G&W laboratories where he was charged with leading the design of a Total Rewards operating model, creating a compensation philosophy and structure, and redesigning their HRIS system.Currently he is the Senior Director of Total Rewards & HRIS at Fragomen where he oversees Total Rewards, performance management and HRIS. In his time, he has developed a new operating model for how Total Rewards provides services to HR and the business and has implemented a global framework for consistent titling and career paths. The recent focus of Shyam and his team has been working to enhance the communication and marketing of Fragomen’s Total Rewards programs in each country to ensure employees are better educated and derive value from all the company’s offerings.

Viðmælandi þessa þáttar, Guðbjörg Edda Eggertsdóttir (eða Edda eins og hún er kölluð), hefur átt langan og farsælan feril sem einn af lykilstjórnendum í Actavis og forverum þess fyrirtækis, Pharmaco og Delta. Í viðtalinu lýsir Edda hvernig lyfjaframleiðsla varð til sem atvinnugrein á Íslandi og þróaðist í að verða einn af burðarstólpum atvinnulífsins. Fyrirtækin Pharmaco og Delta voru leiðandi í þeirri uppbyggingu en þau fyrirtæki byrjuðu sem eitt, slitu svo samvistum en tóku aftur saman 2002 og breyttu síðan nafninu í Actavis. Á árunum 1999-2008 margfaldaðist umfang starfsemi Actavis erlendis og félagið réðst í á annan tug yfirtakna og varð loks að þriðja stærsta samheitalyfjafyrirtæki heims. Edda sem hóf störf hjá félaginu árið 1980 vann sig upp og varð aðstoðarforstjóri Actavis Group árið 2008 og svo forstjóri Actavis á Íslandi 2010 þar til hún lét af störfum árið 2014. Árið eftir komst Actavis í eigu Teva og hætti stuttu síðar lyfjaframleiðslu á Íslandi. Í viðtalinu deilir hún þessari sögu sinni og félagsins með okkur. Þess má geta að Edda hefur hlotið fálkaorðuna fyrir framlag sitt til uppbyggingar íslensks atvinnulífs. Edda hefur setið í ótal stjórnum undanfarin ár þ.m.t. hjá Össur sem og stjórnarformaður vísissjóðsins Brunns. Hún hefur sérstaka ástríðu fyrir nýsköpun og að styðja við framgang kynsystra sinna á því sviði. Njótið vel

The U.S. Supreme Court is no stranger to antitrust law. Jaime Santos, a partner in Goodwin Procter's appellate group, joins Christina Ma and John Roberti to explore recent Supreme Court antitrust cases, including FTC v. Actavis, Ohio v. American Express, and Apple v. Pepper. Listen to this episode to learn more about how the changing Supreme Court bench is likely to impact antitrust cases in the years to come. Related Links: Apple v. Pepper SCOTUS decision  Ohio v. American Express SCOTUS decision  FTC v. Actavis SCOTUS decision  FTC/DOJ Rift Over Qualcomm Hosted by: Christina Ma, Associate, Wachtell Lipton and John Roberti, Partner, Allen & Overy LLP

The use of Viagra as treatment for erectile dysfunction is well known but there are alternatives that exist which arguably work more effectively. In this episode we examine a patent relating to the dosage used for one such alternative, Cialis. However in order to achieve a patent there has to be an 'inventive step' taken and so the question in this case is whether simply working out the correct dosage is enough to qualify. We also consider the latest updates on progress towards the Unified Patent Court. Music from bensound.com

“It is important that you start with the big picture” - Dr. Manfred Stapff This is episode Dr. Manfred Stapff, Chief Medical Officer at TriNetX shares with us the use and application of real-world data in clinical trial. Manfred Stapff is a physician and board-certified clinical pharmacologist with an extensive career in clinical and pharmaceutical medicine. He was formerly an Executive Director at Actavis, Forest Laboratories, and Merck and also served as a Medical Officer in the German Air Force. Manfred earned his MD and Ph.D. from the Ludwig Maximilian University of Munich. In this interview, Manfred shares his personal story as a general physician for pilots to an industry professional in clinical trials. Manfred also has exceptional advice for physicians looking to get into clinical research. To wrap up, we talk about his role as a liaison between medical science and clinical operations.   I hope you enjoy this interview with Dr. Manfred Stapff. Listen to it on iTunes.Stream by clicking here.Download as an MP3 by right-clicking here and choosing “save as.” Selected Links from the Episode: Connect with Manfred LinkedIn Lancet Drug Information Association (DIA) Association of Clinical Research Professionals (ACRP) Food and Drug Administration (FDA) Journal of Clinical Hypertension American Heart Association (AHA) New England Journal of Medicine (NJEM) TriNetX Merck Good Clinical Practice ICH Show Notes: About TriNetX [02:15] The changing landscape in protocol design [04:16] How TriNetX is helping scientist and health care organizations [06:57] What types of people are companies like TriNetX hiring [10:54] Transitioning from general physician for pilots to Merck [13:32] Advice for medical school students and graduates interested in clinical research [18:12] Working at CROs - what to expect [23:27] Why patient enrollment is challenging [25:29] Why should sites consider being part of networks such as TriNetX [28:11] How clinical (medical) and industry can be advantageous to you [31:08] Importance of doing the “dirty work” in clinical research [32:46] Importance of doing the “dirty work” in clinical research [32:46] Being open to other people’s opinions [36:30] Dealing with tension between science and clinical operations [28:43] Keeping yourself informed about new clinical treatments and scientific findings [46:41] QUESTION: What was most useful for you in this episode? Leave me a comment below and thanks for listening.

Trading Block: Trade bodies urge regulators to sort out derivatives reporting. Stocks to watch: CVS, Lumber Liquidators, Actavis. CBOE extends VIX and SPX options trading hours as global growth in VIX continues to build.   Odd Block: Puts trade in SPDR S&P Homebuilders ETF (XHB), calls trade in iShares MSCI Germany Index (EWG), and calls roll in TASER International, Inc. (TASR).     Strategy Block: Tosaw discusses hedging bond portfolios.   Option Pit Mystery Block: Sebastian discusses crisis management.     Around the Block: Earnings: Oracle, Rite Aid & FedEx Highlight Quiet Earnings Week.

FTC v. Actavis, Inc. | 03/25/13 | Docket #: 12-416